Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 51241-51250 Newer>

The Motley Fool August 19, 2011 Jordan DiPietro	Should You Buy and Hold Family Dollar Stores? It's beneficial to look at the industry picture and not just Family Dollar Stores in isolation.
The Motley Fool August 18, 2011 Tim Beyers	BlackBerry and Blue, Again The reviews are in for Research In Motion's newest BlackBerry Bold 9900, and they're ... average.
The Motley Fool August 18, 2011 Rex Moore	TIBCO's Growth May Not Be What It Seems Here are TIBCO Software's numbers, as well as a bonus look at a few other companies in its industry.
The Motley Fool August 18, 2011 Rex Moore	2 Positive Signs for RealD RealD appears to be in good shape in terms of the intangible assets ratio and tangible book value.
The Motley Fool August 18, 2011 Todd Wenning	What Does Medtronic Do With Its Free Cash? Is it a good steward of shareholder capital?
The Motley Fool August 18, 2011 Ilan Moscovitz	Should You Buy and Hold CenturyLink? What should you look for when investing for retirement? Here are CenturyLink's stats compared with three of its closest competitors.
The Motley Fool August 18, 2011 Brian Orelli	Running the Correct Trial Isn't Enough MELA Sciences' stock is up on claim that their trial meets FDA guidance, but they still need to prove that the device actually works.
The Motley Fool August 18, 2011 Eric Bleeker	Today's Top Tech Stories: Storage and Networking Stocks Collapse, and Broken IPO Dreams An HP spinoff, Tudou bombs, and companies struggle to keep up guidance in a choppy economy.
The Motley Fool August 18, 2011 Ilan Moscovitz	Cypress Semiconductor Is Cheaper Than You Think Cypress tends to generate more free cash flow than net income, suggesting that the company's stock might be a bit cheaper than many investors realize.
The Motley Fool August 18, 2011 Brian Orelli	A Poke in the Eye From the FDA FDA extends its review of Regeneron Pharmaceuticals' macular degeneration drug by three months.
<Older 51241-51250 Newer> Return to current articles.